Stocks · News reference

Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Aug 14, 2026, 1:10 PMBenzinga Newsdesk

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 4:31 PMBenzinga Newsdesk
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.
Read original at benzinga
FATE
BenzingaAug 14, 2026, 2:59 PMBenzinga Newsdesk
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.
Read original at benzinga
FATE
BenzingaAug 14, 2026, 11:05 AMBenzinga Newsdesk
Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sitesTrial advances FT819 toward a potential accelerated regulatory pathway
Read original at benzinga
FATE